AstraZeneca: Strensiq Successor Fails Phase 3, Market Expansion Halted AstraZeneca's Strensiq successor missed primary endpoint. Phase 3 trial results were negative. Rare metabolic disease treatment impacted. Market expansion plans now face doubt. AstraZeneca's unnamed Strensiq successor, a follow-on asset for a rare metabolic disease, failed its pivotal Phase 3 trial. The study did not meet its primary endpoint, which was likely a statistically significant improvement in a key biomarker or clinical outcome measure compared to placebo or standard of care. This outcome derails AstraZeneca's strategy to expand its rare disease franchise beyond existing indications. Under FDA and EMA regulations, a failed primary endpoint in a Phase 3 trial typically precludes regulatory submission for approval. AstraZeneca will now likely conduct a thorough data review to assess any secondary endpoints or subgroup analyses. Without a compelling rationale, further development for this specific indication is improbable. This aligns with 21 CFR 314.105 regarding substantial evidence of effectiveness for new drug applications. This setback benefits competitors developing treatments for similar rare metabolic conditions. Ultragenyx Pharmaceutical and Amicus Therapeutics, with their respective rare disease pipelines, could see increased market opportunity. AstraZeneca's immediate focus will shift to other pipeline assets. The company must now re-evaluate its rare disease strategy for 2027.